Abstract
Background: Obstructive Sleep Apnoea (OSA) is associated with an increased risk of pain in patients with Type 2 diabetes (T2D). Hence, it is plausible that continuous positive airway pressure (CPAP) might reduce pain in T2D.
Method: We conducted an open-label multicentre (13 centres) feasibility randomised control trial (RCT) in which patients with T2D and OSA (apnoea hypopnea index AHI ≥ 10 events/hour) were randomised to CPAP vs no CPAP over 2 years. Participants with a resting oxygen saturation <90%, a central apnoea index >15/hrs or Epworth Sleepiness Score (ESS) >= 11 were excluded. The primary outcomes of this trial were related to feasibility. In this abstract, we report on the secondary outcome related to pain which was assessed using the short firm Mcgail pain questionnaire SFMPQ.
Results: Eighty-three patients were randomised to CPAP vs no CPAP (43 vs 40) with a median [IQR] follow-up of 645 [545,861] days. The study population mean (SD) age was 62.5 (10.9) years, and diabetes duration was 12.2(7.9) years. 89.1 % (n=74) were white European ethnicity, 71.1% (n=59) were men, 77.7% (n=59) had obesity, and 48.2% (n=40) were prescribed insulin. The intention-to-treat analysis is summarised in Table 1.
Conclusion: CPAP might have a favourable impact on reducing pain. However, an adequately powered RCT is needed to test this.
Method: We conducted an open-label multicentre (13 centres) feasibility randomised control trial (RCT) in which patients with T2D and OSA (apnoea hypopnea index AHI ≥ 10 events/hour) were randomised to CPAP vs no CPAP over 2 years. Participants with a resting oxygen saturation <90%, a central apnoea index >15/hrs or Epworth Sleepiness Score (ESS) >= 11 were excluded. The primary outcomes of this trial were related to feasibility. In this abstract, we report on the secondary outcome related to pain which was assessed using the short firm Mcgail pain questionnaire SFMPQ.
Results: Eighty-three patients were randomised to CPAP vs no CPAP (43 vs 40) with a median [IQR] follow-up of 645 [545,861] days. The study population mean (SD) age was 62.5 (10.9) years, and diabetes duration was 12.2(7.9) years. 89.1 % (n=74) were white European ethnicity, 71.1% (n=59) were men, 77.7% (n=59) had obesity, and 48.2% (n=40) were prescribed insulin. The intention-to-treat analysis is summarised in Table 1.
Conclusion: CPAP might have a favourable impact on reducing pain. However, an adequately powered RCT is needed to test this.
| Original language | English |
|---|---|
| Publication status | Published - 1 Oct 2023 |
| Event | 33rd Annual Meeting of Neurodiab conference - Thessaloniki, Greece Duration: 28 Sept 2023 → 1 Oct 2023 |
Conference
| Conference | 33rd Annual Meeting of Neurodiab conference |
|---|---|
| Country/Territory | Greece |
| City | Thessaloniki |
| Period | 28/09/23 → 1/10/23 |
